Myelofibrosis medical therapy: Difference between revisions
Varun Kumar (talk | contribs) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Myelofibrosis}} | {{Myelofibrosis}} | ||
{{CMG}} | {{CMG}} | ||
Revision as of 20:23, 17 September 2012
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis medical therapy |
|
Risk calculators and risk factors for Myelofibrosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical therapy
Other treatment options are largely supportive, and do not alter the course.[1] These options may include regular folic acid, allopurinol or blood transfusions. Dexamethasone, alpha-interferon and hydroxycarbamide may play a role.
Lenalidomide and Thalidomide may be used in its treatment, though they can cause gout and leave the patient susceptible to diseases such as pneumonia.
Frequent blood transfusions may also be required.
The patient with the myelofibrosis should be tested for Tuberculosis even if the patient doesn't manifest the symptoms of TB. There is strong evidence of myelofibrois improvement with the antituberculous treatment.
References
- ↑ Kröger N, Mesa RA (2008). "Choosing between stem cell therapy and drugs in myelofibrosis". Leukemia. 22 (3): 474–86. doi:10.1038/sj.leu.2405080. PMID 18185525. Unknown parameter
|month=ignored (help)